Lemonex Inc
- Biotech or pharma, therapeutic R&D
Lemonex has developed a drug delivery platform technology based on porous silica nanoparticles called DegradaBALL. It has applied this to siRNA therapeutics (LEM-S401) and mRNA vaccines (LEM-mR203) and completed phase 1 clinical trials on healthy adults, respectively. Recently, Lemonex has been focusing on mRNA vaccines, and received an award from CEPI in December 2023. Through this, we conducted a phase 1 clinical trial of LEM-mR203 on healthy adults, and confirmed excellent safety and tolerability results, as well as high temperature stability and long-term storage potential. In April 2025, we were selected as the sole lead organization for the 'Pandemic mRNA Vaccine Development Support' project worth approximately USD $360 million hosted by KDAC.
https://cepi.net/news_cepi/cepi-partners-with-lemonex-to-advance-mrna-vaccine-delivery-against-future-pandemic-threats/
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}